Document Type : Original Article(s)
Authors
- Manijeh Tabrizi 1
- Sadroddin Mahdipour 1
- Seyyedeh Azade Hoseini Nouri 1
- Vahid Aminzadeh 1
- Zahra Ghadiri 1
- Maryam Shahrokhi 2
1 Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran
2 Bio Environmental Health Hazards Research Center, Jiroft University of Medical Sciences, Jiroft, Iran
Abstract
Background: Prolonged indirect hyperbilirubinemia (PIH) is defined as bilirubin levels >10 mg/dL for more than 14 days in term infants and 21 days in preterm infants. Although the role of ursodeoxycholic acid (UDCA) as an adjunct to phototherapy has been evaluated, evidence in PIH remains limited. Therefore, this study aimed to investigate the effects of UDCA on PIH.
Methods: This randomized controlled trial was conducted on infants with PIH in Rasht, Iran, (July 2023-July 2024). Participants were enrolled through consecutive sampling and randomly assigned to intervention or control groups. The intervention group received 10 mg/Kg/day UDCA for 5 days. The control group received no intervention and was observed. Bilirubin, ABO, and Rh blood group status were measured on day 1 and day 5. Data were analyzed using an independent samples t test with SPSS software (version 26). P<0.05 was considered statistically significant.
Results: Fifty-eight patients were included, with 29 in each group. Both groups showed a significant reduction in bilirubin levels over 5 days (control: 12.26±1.65 to 10.09±2.74 mg/dL; intervention: 11.96±1.48 to 9.07±3.45 mg/dL; P<0.001). The mean bilirubin reduction was 2.17±2.50 mg/dL in the control group and 2.89±3.00 mg/dL in the intervention group, with no statistically significant difference between groups (P=0.323). On day 5, bilirubin levels were 10.09±2.74 mg/dL in the control group and 9.07±3.45 mg/dL in the intervention group (P=0.216). ABO incompatibility was associated with lower bilirubin levels on day 5 in the intervention group (7.26±2.33 vs. 9.76±3.61 mg/dL; P=0.041). Rh incompatibility was correlated with greater bilirubin reduction over 5 days (4.98±1.54 vs. 2.45±3.07 mg/dL; P=0.025).
Conclusion: Five-day UDCA therapy did not significantly reduce bilirubin levels in infants with PIH.
Highlights
Manijeh Tabrizi (Google Scholar)
Seyyedeh Azade Hoseini Nouri (Google Scholar)
Keywords
- Ullah S, Rahman K, Hedayati M. Hyperbilirubinemia in neonates: types, causes, clinical examinations, preventive measures and treatments: a narrative review article. Iran J Public Health. 2016;45:558-68. PubMed PMID: 27398328; PubMed Central PMCID: PMC4935699.
- Al-Musawi ZM, Al-Musawi SN, Ali IMM. The role of oral phenobarbital therapy in the management of neonates with prolonged unconjugated hyperbilirubinemia. Alqadisiah Med J. 2019;15:57-66.
- Ozdemir A, Kurtoglu S, Halis H, Bastug O. An evaluation of ursodeoxycholic acid treatment in prolonged unconjugated hyperbilirubinemia due to breast milk. Niger J Clin Pract. 2023;26:1226-33. doi: 10.4103/njcp.njcp_216_22. PubMed PMID: 37794533.
- Bratton S, Cantu RM, Stern M, Dooley W. Breast milk jaundice (nursing). Treasure Island: StatPearls; 2023.
- Ansong-Assoku B, Adnan M, Daley S, Ankola P. Neonatal jaundice. Treasure Island: StatPearls; 2024.
- Asinobi IN. Breastmilk jaundice – could it be more common than we realize? J Adv Med Med Res. 2023;35:29-35. doi: 10.9734/jammr/2023/v35i125034.
- Ughasoro MD, Adimorah GN, Chukwudi NK, Nnakenyi ID, Iloh KK, Udemba CE. Reductive effect of ursodeoxycholic acid on bilirubin levels in neonates on phototherapy. Clin Exp Gastroenterol. 2019;12:349-54. doi: 10.2147/CEG.S207523. PubMed PMID: 31534356; PubMed Central PMCID: PMC6681162.
- Honar N, Ghashghaei Saadi E, Saki F, Pishva N, Shakibazad N, Hosseini Teshnizi S. Effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy. J Pediatr Gastroenterol Nutr. 2016;62:97-100. doi: 10.1097/MPG.0000000000000874. PubMed PMID: 26020375.
- Akefi R, Hashemi SM, Alinejad S, Almasi-Hashiani A. The effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy: a randomized clinical trial. J Matern Fetal Neonatal Med. 2022;35:4075-80. doi: 10.1080/14767058.2020.1846705. PubMed PMID: 33225772.
- Gharehbaghi MM, Sani AM, Refeey M. Evaluating the effects of different doses of ursodeoxycholic acid on neonatal jaundice. Turk J Pediatr. 2020;62:424-30. doi: 10.24953/turkjped.2020.03.009. PubMed PMID: 32558416.
- Mirzarahimi M, Barak M, Moghaddam SS, Moghaddam EE. Effect of ursodeoxycholic acid (USDA) on indirect hyperbilirubinemia in neonates treated with phototherapy. Prog Asp Pediatr Neonatol. 2019;2:138-41. doi: 10.32474/PAPN.2019.02.000136.
- Shahramian I, Tabrizian K, Ostadrahimi P, Afshari M, Soleymanifar M, Bazi A. Therapeutic effects of ursodeoxycholic acid in neonatal indirect hyperbilirubinemia: a randomized double-blind clinical trial. Arch Anesthesiol Crit Care. 2019;5:1211. doi: 10.18502/aacc.v5i3.1211.
- Lazarus G, Francie J, Roeslani RD, Saldi SRF, Oswari H. Role of ursodeoxycholic acid in neonatal indirect hyperbilirubinemia: a systematic review and meta-analysis of randomized controlled trials. Ital J Pediatr. 2022;48:179. doi: 10.1186/s13052-022-01372-w. PubMed PMID: 36253867; PubMed Central PMCID: PMC9575272.
- Meena D, Bhardwaj D, Gupta D, Jagrwal D. Effect of oral ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy at tertiary care centre. Eur J Mol Clin Med. 2021;7:5738-47.
- Huseynova RA. Effect of ursodeoxycholic acid in unconjugated hyperbilirubinemia in the term neonates treated with phototherapy: a systematic review. Baku: Azerbaijan Medical University; 2022. doi: 10.5005/jp-journals-11002-0046.
- Hassan AM, Abdulrahman A, Husain RH. Effect of ursodeoxycholic acid in lowering neonatal indirect hyperbilirubinemia: a randomized controlled trial. Merit Res J Med Med Sci. 2015;3:402-5.
- Jafari S, Khan KA, Bhatnagar S, Srivastava G, Nanda C, Chandra A. Role of ursodeoxycholic acid in neonates with indirect hyperbilirubinemia—an open labelled randomised control trial. Int J Contemp Pediatr. 2018;5:432-5. doi: 10.18203/2349-3291.ijcp20180530.
- Kuitunen I, Kiviranta P, Sankilampi U, Renko M. Ursodeoxycholic acid as adjuvant treatment to phototherapy for neonatal hyperbilirubinemia: a systematic review and meta-analysis. World J Pediatr. 2022;18:589-97. doi: 10.1007/s12519-022-00563-z. PubMed PMID: 35689782; PubMed Central PMCID: PMC9376150.
- Sarathy L, Chou JH, Romano-Clarke G, Darci KA, Lerou PH. Bilirubin measurement and phototherapy use after the AAP 2022 newborn hyperbilirubinemia guideline. Pediatrics. 2024;153:e2023063323. doi: 10.1542/peds.2023-063323. PubMed PMID: 38482582.
- Bagcı O, Varal IG, Dogan P, Özkan H, Köksal N. The role of probiotics in breast milk jaundice: results of a prospective study in a tertiary care center. Pediatr Int. 2025;67:e70043. doi: 10.1111/ped.70043. PubMed PMID: 40452378.
- Tabrizian K, Shahramian I, Bazi A, Afshari M, Ghaemi A. Alleviating effects of ursodeoxycholic acid in children with acute hepatitis A infection: a randomized clinical trial. Hepat Mon. 2019;19:e93552. doi: 10.5812/hepatmon.86719.
- Kazem Sabzehei M, Basiri B, Gohari Z, Bazmamoun H. Etiologies of prolonged unconjugated hyperbilirubinemia in neonates admitted to neonatal wards. Iran J Neonatol. 2015;6:37-42.
- Rezaie M, Gholami R, Jafari M, Haghighinejad H. Evaluating the effect of ursodeoxycholic acid on total bilirubin of neonates with glucose-6-phosphate dehydrogenase deficiency complicated by indirect hyperbilirubinaemia. J Paediatr Child Health. 2021;57:1175-81. doi: 10.1111/jpc.15378. PubMed PMID: 33851435.
- Farhadi R, Keyhanian E, Naderisorki M, Nadi Ghara A. Effects of two different doses of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates with glucose-6-phosphate dehydrogenase deficiency treated with phototherapy: a randomized controlled trial. Glob Pediatr Health. 2023;10:2333794X231156055. doi: 10.1177/2333794X231156055. PubMed PMID: 36860239; PubMed Central PMCID: PMC9963223.
- Simmons DP, Savage WJ. Hemolysis from ABO incompatibility. Hematol Oncol Clin North Am. 2015;29:429-43. doi: 10.1016/j.hoc.2015.01.003. PubMed PMID: 26043383.
- Sahin K, Aydın T, Bilgin DD, Büyükkayhan D, Elevli M. Comparison of demographic characteristics and haematological parameters in newborns with and without haemolytic disease due to ABO incompatibility. BMC Pediatr. 2025;25:582. doi: 10.1186/s12887-025-05935-8. PubMed PMID: 40739623; PubMed Central PMCID: PMC12308972.
- Mahapatra S, Patra K, Panda S, Behuria S, Sahu PK, Majhi MM. Hyperbilirubinemia in neonates with blood group incompatibilities - a bane or a boon for the management. Transfus Clin Biol. 2025;32:82-6. doi: 10.1016/j.tracli.2025.01.004. PubMed PMID: 39814259.
- Parastatidou S, Tsantes AG, Emmanouil CC, Konstantinidi A, Kapetanaki A, Sokou R. Neonatal hemolytic jaundice: causes, diagnostic approach, and management. Children (Basel). 2025;12:666. doi: 10.3390/children12060666. PubMed PMID: 40564624; PubMed Central PMCID: PMC12190970.
- El-Gendy F, Bahbah W, Al Kafory E. Effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy. Menoufia Med J. 2019;32:1059-63. doi: 10.4103/mmj.mmj_885_17.
)